[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fxB35RA5pV2aavYg6EoRVJr4tZh1YQG6XTa-o700uMl0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":8,"topConditions":11,"upcomingReadouts":30,"phaseBuckets":31,"rows":38},"Nobelpharma",[4],34,false,0,25,2156,[12,15,18,20,22,24,26,28],{"name":13,"count":14},"Dysmenorrhea",6,{"name":16,"count":17},"Acute Pain in Herpes Zoster",2,{"name":19,"count":17},"Healthy",{"name":21,"count":17},"Malignant Glioma",{"name":23,"count":17},"Tuberous Sclerosis",{"name":25,"count":17},"Angiofibroma",{"name":27,"count":17},"Hypomelanotic Macule",{"name":29,"count":17},"Plaque",[],[32,33,34,35,36,37],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[39,93,139,170,212,258,284,309,327,352,370,394,422,440,466,484,508,533,562,580,598,623,647,672,690,716,744,762,780,802,838,860,884,909,934],{"intervention":40,"totalTrials":41,"cells":42},"NPC-01",4,{"EARLY_PHASE1":43,"PHASE1":45,"PHASE2":47,"PHASE3":49,"PHASE4":89,"NA":91},{"trials":44,"activeCount":8},[],{"trials":46,"activeCount":8},[],{"trials":48,"activeCount":8},[],{"trials":50,"activeCount":8},[51,62,71,80],{"nctId":52,"briefTitle":53,"status":54,"phases":55,"primaryCompletion":56,"completion":56,"start":57,"enrollment":58,"conditions":59,"interventions":60},"NCT01253824","Pharmacodynamics of NPC-01\u002FIKH-01; Effect of NPC-01\u002FIKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers","COMPLETED",[35],"2011-07","2011-01",14,[19],[40,61],"IKH-01",{"nctId":63,"briefTitle":64,"status":54,"phases":65,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":69,"interventions":70},"NCT01129102","Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea",[35],"2011-04","2010-05",215,[13],[40,61],{"nctId":72,"briefTitle":73,"status":54,"phases":74,"primaryCompletion":75,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT01246791","Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers",[35],"2011-05","2010-11",12,[19],[40],{"nctId":81,"briefTitle":82,"status":54,"phases":83,"primaryCompletion":84,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":88},"NCT00902746","Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis",[35],"2012-02","2009-05",149,[13],[40],{"trials":90,"activeCount":8},[],{"trials":92,"activeCount":8},[],{"intervention":94,"totalTrials":95,"cells":96},"NPC-06",3,{"EARLY_PHASE1":97,"PHASE1":99,"PHASE2":101,"PHASE3":123,"PHASE4":135,"NA":137},{"trials":98,"activeCount":8},[],{"trials":100,"activeCount":8},[],{"trials":102,"activeCount":8},[103,114],{"nctId":104,"briefTitle":105,"status":106,"phases":107,"primaryCompletion":108,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT03773055","Phase II Clinical Trial of NPC-06 in Patients With Neuropathic Pain in Cancer","TERMINATED",[34],"2020-09-30","2019-04-03",7,[112],"Neuropathic Pain in Cancer",[94],{"nctId":115,"briefTitle":116,"status":106,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":120,"conditions":121,"interventions":122},"NCT04139330","NPC-06 to Acute Pain in Herpes Zoster",[34],"2021-02-28","2019-11-21",16,[16],[94],{"trials":124,"activeCount":8},[125],{"nctId":126,"briefTitle":127,"status":54,"phases":128,"primaryCompletion":129,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT05480553","NPC-06 to Pain Associated With Acute Herpes Zoster",[35],"2023-05-29","2023-08-23","2022-08-05",51,[16],[94],{"trials":136,"activeCount":8},[],{"trials":138,"activeCount":8},[],{"intervention":61,"totalTrials":95,"cells":140},{"EARLY_PHASE1":141,"PHASE1":143,"PHASE2":145,"PHASE3":147,"PHASE4":166,"NA":168},{"trials":142,"activeCount":8},[],{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[],{"trials":148,"activeCount":8},[149,153,162],{"nctId":52,"briefTitle":53,"status":54,"phases":150,"primaryCompletion":56,"completion":56,"start":57,"enrollment":58,"conditions":151,"interventions":152},[35],[19],[40,61],{"nctId":154,"briefTitle":155,"status":54,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT00746096","Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea",[35],"2009-09","2008-09",115,[13],[61],{"nctId":63,"briefTitle":64,"status":54,"phases":163,"primaryCompletion":66,"completion":66,"start":67,"enrollment":68,"conditions":164,"interventions":165},[35],[13],[40,61],{"trials":167,"activeCount":8},[],{"trials":169,"activeCount":8},[],{"intervention":171,"totalTrials":95,"cells":172},"NPC-12G gel",{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":208,"NA":210},{"trials":174,"activeCount":8},[],{"trials":176,"activeCount":8},[],{"trials":178,"activeCount":8},[],{"trials":180,"activeCount":8},[181,191,200],{"nctId":182,"briefTitle":183,"status":106,"phases":184,"primaryCompletion":185,"completion":185,"start":186,"enrollment":187,"conditions":188,"interventions":190},"NCT04461886","A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I",[35],"2021-12-07","2020-07-08",100,[189],"Neurofibromatosis",[171],{"nctId":192,"briefTitle":193,"status":54,"phases":194,"primaryCompletion":195,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":199},"NCT02634931","Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex",[35],"2018-10","2015-12",94,[23,25,27,29],[171],{"nctId":201,"briefTitle":202,"status":54,"phases":203,"primaryCompletion":204,"completion":204,"start":196,"enrollment":205,"conditions":206,"interventions":207},"NCT02635789","Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)",[35],"2016-10",62,[23,25,27,29],[171],{"trials":209,"activeCount":8},[],{"trials":211,"activeCount":8},[],{"intervention":213,"totalTrials":95,"cells":214},"NPC-02",{"EARLY_PHASE1":215,"PHASE1":217,"PHASE2":219,"PHASE3":221,"PHASE4":254,"NA":256},{"trials":216,"activeCount":8},[],{"trials":218,"activeCount":8},[],{"trials":220,"activeCount":8},[],{"trials":222,"activeCount":8},[223,234,245],{"nctId":224,"briefTitle":225,"status":54,"phases":226,"primaryCompletion":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT00212355","Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson's Disease in Japan.",[35],"2008-04","2009-01","2005-03",37,[232],"Wilson's Disease",[213],{"nctId":235,"briefTitle":236,"status":54,"phases":237,"primaryCompletion":238,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":244},"NCT02321865","Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency",[35],"2015-11","2015-11-24","2015-01-21",43,[243],"Zinc Deficiency",[213],{"nctId":246,"briefTitle":247,"status":54,"phases":248,"primaryCompletion":238,"completion":238,"start":249,"enrollment":250,"conditions":251,"interventions":252},"NCT02337569","A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency",[35],"2015-01",57,[243],[213,253],"Placebos",{"trials":255,"activeCount":8},[],{"trials":257,"activeCount":8},[],{"intervention":259,"totalTrials":260,"cells":261},"Sargramostim",1,{"EARLY_PHASE1":262,"PHASE1":264,"PHASE2":266,"PHASE3":268,"PHASE4":280,"NA":282},{"trials":263,"activeCount":8},[],{"trials":265,"activeCount":8},[],{"trials":267,"activeCount":8},[],{"trials":269,"activeCount":8},[270],{"nctId":271,"briefTitle":272,"status":54,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},"NCT04642950","A Phase II\u002FIII Study of Sargramostim",[34,35],"2021-10-25","2020-12-17",70,[278],"COVID-19",[259],{"trials":281,"activeCount":8},[],{"trials":283,"activeCount":8},[],{"intervention":285,"totalTrials":260,"cells":286},"Norethisterone,Ethinylestradiol",{"EARLY_PHASE1":287,"PHASE1":289,"PHASE2":291,"PHASE3":293,"PHASE4":305,"NA":307},{"trials":288,"activeCount":8},[],{"trials":290,"activeCount":8},[],{"trials":292,"activeCount":8},[],{"trials":294,"activeCount":8},[295],{"nctId":296,"briefTitle":297,"status":54,"phases":298,"primaryCompletion":299,"completion":300,"start":301,"enrollment":187,"conditions":302,"interventions":303},"NCT00212342","Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Dysmenorrhea",[35],"2006-01","2006-03","2004-12",[13],[285,304],"Sugar pill",{"trials":306,"activeCount":8},[],{"trials":308,"activeCount":8},[],{"intervention":304,"totalTrials":260,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":323,"NA":325},{"trials":312,"activeCount":8},[],{"trials":314,"activeCount":8},[],{"trials":316,"activeCount":8},[],{"trials":318,"activeCount":8},[319],{"nctId":296,"briefTitle":297,"status":54,"phases":320,"primaryCompletion":299,"completion":300,"start":301,"enrollment":187,"conditions":321,"interventions":322},[35],[13],[285,304],{"trials":324,"activeCount":8},[],{"trials":326,"activeCount":8},[],{"intervention":328,"totalTrials":260,"cells":329},"NPC-12Y gel",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":348,"NA":350},{"trials":331,"activeCount":8},[],{"trials":333,"activeCount":8},[],{"trials":335,"activeCount":8},[],{"trials":337,"activeCount":8},[338],{"nctId":339,"briefTitle":340,"status":54,"phases":341,"primaryCompletion":342,"completion":342,"start":343,"enrollment":241,"conditions":344,"interventions":346},"NCT05495425","Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC",[35],"2024-10-30","2022-06-01",[345],"Tuberous Sclerosis Complex",[328,347],"NPC-12Y placebo gel",{"trials":349,"activeCount":8},[],{"trials":351,"activeCount":8},[],{"intervention":347,"totalTrials":260,"cells":353},{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":366,"NA":368},{"trials":355,"activeCount":8},[],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[362],{"nctId":339,"briefTitle":340,"status":54,"phases":363,"primaryCompletion":342,"completion":342,"start":343,"enrollment":241,"conditions":364,"interventions":365},[35],[345],[328,347],{"trials":367,"activeCount":8},[],{"trials":369,"activeCount":8},[],{"intervention":371,"totalTrials":260,"cells":372},"NPC-07 for oral administration",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":390,"NA":392},{"trials":374,"activeCount":8},[],{"trials":376,"activeCount":8},[],{"trials":378,"activeCount":8},[],{"trials":380,"activeCount":8},[381],{"nctId":382,"briefTitle":383,"status":54,"phases":384,"primaryCompletion":385,"completion":385,"start":386,"enrollment":387,"conditions":388,"interventions":389},"NCT01167322","Study of NPC-07 for Fluorescence-guided Resection of Malignant Gliomas",[35],"2011-12","2010-08",45,[21],[371],{"trials":391,"activeCount":8},[],{"trials":393,"activeCount":8},[],{"intervention":395,"totalTrials":260,"cells":396},"NPC-09",{"EARLY_PHASE1":397,"PHASE1":399,"PHASE2":401,"PHASE3":403,"PHASE4":418,"NA":420},{"trials":398,"activeCount":8},[],{"trials":400,"activeCount":8},[],{"trials":402,"activeCount":8},[],{"trials":404,"activeCount":8},[405],{"nctId":406,"briefTitle":407,"status":54,"phases":408,"primaryCompletion":409,"completion":409,"start":410,"enrollment":58,"conditions":411,"interventions":416},"NCT04671472","Efficacy Confirmation Study of NPC-09",[35],"2022-03-29","2021-02-08",[412,413,414,415],"GNE Myopathy","Distal Myopathy With Rimmed Vacuoles (DMRV)","Hereditary Inclusion Body Myopathy (hIBM)","Nonaka Disease",[395,417],"NPC-09 placebo",{"trials":419,"activeCount":8},[],{"trials":421,"activeCount":8},[],{"intervention":417,"totalTrials":260,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":436,"NA":438},{"trials":425,"activeCount":8},[],{"trials":427,"activeCount":8},[],{"trials":429,"activeCount":8},[],{"trials":431,"activeCount":8},[432],{"nctId":406,"briefTitle":407,"status":54,"phases":433,"primaryCompletion":409,"completion":409,"start":410,"enrollment":58,"conditions":434,"interventions":435},[35],[412,413,414,415],[395,417],{"trials":437,"activeCount":8},[],{"trials":439,"activeCount":8},[],{"intervention":441,"totalTrials":260,"cells":442},"NPC-16 Standard Dosing Regimen Group",{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":462,"NA":464},{"trials":444,"activeCount":8},[],{"trials":446,"activeCount":8},[],{"trials":448,"activeCount":8},[],{"trials":450,"activeCount":8},[451],{"nctId":452,"briefTitle":453,"status":54,"phases":454,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT02362711","Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea",[35],"2017-01","2017-01-28","2015-02",248,[13],[441,461],"NPC-16 Continuous Dosing Regimen Group",{"trials":463,"activeCount":8},[],{"trials":465,"activeCount":8},[],{"intervention":461,"totalTrials":260,"cells":467},{"EARLY_PHASE1":468,"PHASE1":470,"PHASE2":472,"PHASE3":474,"PHASE4":480,"NA":482},{"trials":469,"activeCount":8},[],{"trials":471,"activeCount":8},[],{"trials":473,"activeCount":8},[],{"trials":475,"activeCount":8},[476],{"nctId":452,"briefTitle":453,"status":54,"phases":477,"primaryCompletion":455,"completion":456,"start":457,"enrollment":458,"conditions":478,"interventions":479},[35],[13],[441,461],{"trials":481,"activeCount":8},[],{"trials":483,"activeCount":8},[],{"intervention":485,"totalTrials":260,"cells":486},"Norethindrone,Ethinyl Estradiol",{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":504,"NA":506},{"trials":488,"activeCount":8},[],{"trials":490,"activeCount":8},[],{"trials":492,"activeCount":8},[],{"trials":494,"activeCount":8},[495],{"nctId":496,"briefTitle":497,"status":54,"phases":498,"primaryCompletion":499,"completion":500,"start":501,"conditions":502,"interventions":503},"NCT00212277","Efficacy and Safety,Long-term Study of Low-dose Oral Contraceptive Pill to Treat Dysmenorrhea.",[35],"2006-09","2007-02","2005-02",[13],[485],{"trials":505,"activeCount":8},[],{"trials":507,"activeCount":8},[],{"intervention":509,"totalTrials":260,"cells":510},"Zinc acetate",{"EARLY_PHASE1":511,"PHASE1":513,"PHASE2":515,"PHASE3":517,"PHASE4":529,"NA":531},{"trials":512,"activeCount":8},[],{"trials":514,"activeCount":8},[],{"trials":516,"activeCount":8},[],{"trials":518,"activeCount":8},[519],{"nctId":520,"briefTitle":521,"status":54,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"conditions":526,"interventions":528},"NCT00212368","Efficacy and Safety Study of Zinc Acetate to Treat Wilson's Disease in Japan.",[35],"2005-08","2005-12","2004-10",[527],"Wison's Disease",[509],{"trials":530,"activeCount":8},[],{"trials":532,"activeCount":8},[],{"intervention":534,"totalTrials":260,"cells":535},"NPC-15 Granules Lower Dose",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":558,"NA":560},{"trials":537,"activeCount":8},[],{"trials":539,"activeCount":8},[],{"trials":541,"activeCount":8},[],{"trials":543,"activeCount":8},[544],{"nctId":545,"briefTitle":546,"status":54,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":555},"NCT02757066","Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders",[34,35],"2018-09","2018-09-14","2016-06-16",196,[553,554],"Sleep Disorders","Autism Spectrum Disorder",[534,556,557],"NPC-15 Granules Higher Dose","NPC-15 Placebo Granule",{"trials":559,"activeCount":8},[],{"trials":561,"activeCount":8},[],{"intervention":556,"totalTrials":260,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":576,"NA":578},{"trials":565,"activeCount":8},[],{"trials":567,"activeCount":8},[],{"trials":569,"activeCount":8},[],{"trials":571,"activeCount":8},[572],{"nctId":545,"briefTitle":546,"status":54,"phases":573,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":574,"interventions":575},[34,35],[553,554],[534,556,557],{"trials":577,"activeCount":8},[],{"trials":579,"activeCount":8},[],{"intervention":557,"totalTrials":260,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":588,"PHASE4":594,"NA":596},{"trials":583,"activeCount":8},[],{"trials":585,"activeCount":8},[],{"trials":587,"activeCount":8},[],{"trials":589,"activeCount":8},[590],{"nctId":545,"briefTitle":546,"status":54,"phases":591,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":592,"interventions":593},[34,35],[553,554],[534,556,557],{"trials":595,"activeCount":8},[],{"trials":597,"activeCount":8},[],{"intervention":599,"totalTrials":260,"cells":600},"NPC-11 for intravenous or oral administration.",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":605,"PHASE3":607,"PHASE4":619,"NA":621},{"trials":602,"activeCount":8},[],{"trials":604,"activeCount":8},[],{"trials":606,"activeCount":8},[],{"trials":608,"activeCount":8},[609],{"nctId":610,"briefTitle":611,"status":54,"phases":612,"primaryCompletion":613,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":618},"NCT01408173","Clinical Study of Caffeine for Apnea of Prematurity",[35],"2012-10","2011-08",24,[617],"Apnea of Prematurity",[599],{"trials":620,"activeCount":8},[],{"trials":622,"activeCount":8},[],{"intervention":624,"totalTrials":260,"cells":625},"fosphenytoin",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":643,"NA":645},{"trials":627,"activeCount":8},[],{"trials":629,"activeCount":8},[],{"trials":631,"activeCount":8},[],{"trials":633,"activeCount":8},[634],{"nctId":635,"briefTitle":636,"status":54,"phases":637,"primaryCompletion":638,"completion":638,"start":85,"enrollment":639,"conditions":640,"interventions":642},"NCT00908453","The Study of NPC-06 - Investigation of Safety, Efficacy and Pharmacokinetics of Fosphenytoin",[35],"2010-02",40,[641],"Epilepsy",[624],{"trials":644,"activeCount":8},[],{"trials":646,"activeCount":8},[],{"intervention":648,"totalTrials":260,"cells":649},"Oxcarbazepine",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":668,"NA":670},{"trials":651,"activeCount":8},[],{"trials":653,"activeCount":8},[],{"trials":655,"activeCount":8},[],{"trials":657,"activeCount":8},[658],{"nctId":659,"briefTitle":660,"status":54,"phases":661,"primaryCompletion":662,"completion":662,"start":663,"enrollment":664,"conditions":665,"interventions":667},"NCT01051193","Long-term Safety and Tolerability of TRI476 (Oxcarbazepine) in Children With Inadequately Controlled Partial Onset Seizures",[34,35],"2019-09-30","2010-01-05",88,[666],"Partial Onset Seizures",[648],{"trials":669,"activeCount":8},[],{"trials":671,"activeCount":8},[],{"intervention":253,"totalTrials":260,"cells":673},{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":686,"NA":688},{"trials":675,"activeCount":8},[],{"trials":677,"activeCount":8},[],{"trials":679,"activeCount":8},[],{"trials":681,"activeCount":8},[682],{"nctId":246,"briefTitle":247,"status":54,"phases":683,"primaryCompletion":238,"completion":238,"start":249,"enrollment":250,"conditions":684,"interventions":685},[35],[243],[213,253],{"trials":687,"activeCount":8},[],{"trials":689,"activeCount":8},[],{"intervention":691,"totalTrials":260,"cells":692},"NPC-15",{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":712,"NA":714},{"trials":694,"activeCount":8},[],{"trials":696,"activeCount":8},[],{"trials":698,"activeCount":8},[],{"trials":700,"activeCount":8},[701],{"nctId":702,"briefTitle":703,"status":54,"phases":704,"primaryCompletion":705,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT02757079","Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders",[35],"2018-07","2018-07-06","2016-06-21",99,[553,710],"Neurodevelopmental Disorder",[691],{"trials":713,"activeCount":8},[],{"trials":715,"activeCount":8},[],{"intervention":717,"totalTrials":260,"cells":718},"NPC-21 Low dose",{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":738,"PHASE4":740,"NA":742},{"trials":720,"activeCount":8},[],{"trials":722,"activeCount":8},[],{"trials":724,"activeCount":8},[725],{"nctId":726,"briefTitle":727,"status":54,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":735},"NCT04225923","A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection",[34],"2022-11-02","2023-02-08","2020-06-01",87,[734],"Cytomegalovirus Disease",[717,736,737],"NPC-21 High dose","NPC-21 Placebo",{"trials":739,"activeCount":8},[],{"trials":741,"activeCount":8},[],{"trials":743,"activeCount":8},[],{"intervention":736,"totalTrials":260,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":747,"activeCount":8},[],{"trials":749,"activeCount":8},[],{"trials":751,"activeCount":8},[752],{"nctId":726,"briefTitle":727,"status":54,"phases":753,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":754,"interventions":755},[34],[734],[717,736,737],{"trials":757,"activeCount":8},[],{"trials":759,"activeCount":8},[],{"trials":761,"activeCount":8},[],{"intervention":737,"totalTrials":260,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":765,"activeCount":8},[],{"trials":767,"activeCount":8},[],{"trials":769,"activeCount":8},[770],{"nctId":726,"briefTitle":727,"status":54,"phases":771,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":772,"interventions":773},[34],[734],[717,736,737],{"trials":775,"activeCount":8},[],{"trials":777,"activeCount":8},[],{"trials":779,"activeCount":8},[],{"intervention":781,"totalTrials":260,"cells":782},"NPC-08",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":796,"PHASE4":798,"NA":800},{"trials":784,"activeCount":8},[],{"trials":786,"activeCount":8},[],{"trials":788,"activeCount":8},[789],{"nctId":790,"briefTitle":791,"status":54,"phases":792,"primaryCompletion":66,"completion":66,"start":793,"enrollment":615,"conditions":794,"interventions":795},"NCT00919737","Study of NPC-08 is to Treat for Newly-Diagnosed Malignant Glioma and Recurrent Glioblastoma Multiforme",[33,34],"2009-06",[21],[781],{"trials":797,"activeCount":8},[],{"trials":799,"activeCount":8},[],{"trials":801,"activeCount":8},[],{"intervention":803,"totalTrials":17,"cells":804},"NPC-22",{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":830,"PHASE3":832,"PHASE4":834,"NA":836},{"trials":806,"activeCount":8},[],{"trials":808,"activeCount":8},[809,819],{"nctId":810,"briefTitle":811,"status":54,"phases":812,"primaryCompletion":813,"completion":813,"start":814,"enrollment":639,"conditions":815,"interventions":817},"NCT04203862","A Study of NPC-22 in Healthy Adult Males",[33],"2020-02-04","2019-11-19",[816],"Healthy Adult Subjects",[803,803,803,803,803,818],"NPC-22 Placebo",{"nctId":820,"briefTitle":821,"status":54,"phases":822,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT04503863","An Additional Study of NPC-22 in Healthy Adult Males",[33],"2020-11-06","2021-12-28","2020-07-20",32,[828],"Safety and Pharmacokinetics",[803,803,818],{"trials":831,"activeCount":8},[],{"trials":833,"activeCount":8},[],{"trials":835,"activeCount":8},[],{"trials":837,"activeCount":8},[],{"intervention":818,"totalTrials":17,"cells":839},{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":858},{"trials":841,"activeCount":8},[],{"trials":843,"activeCount":8},[844,848],{"nctId":810,"briefTitle":811,"status":54,"phases":845,"primaryCompletion":813,"completion":813,"start":814,"enrollment":639,"conditions":846,"interventions":847},[33],[816],[803,803,803,803,803,818],{"nctId":820,"briefTitle":821,"status":54,"phases":849,"primaryCompletion":823,"completion":824,"start":825,"enrollment":826,"conditions":850,"interventions":851},[33],[828],[803,803,818],{"trials":853,"activeCount":8},[],{"trials":855,"activeCount":8},[],{"trials":857,"activeCount":8},[],{"trials":859,"activeCount":8},[],{"intervention":861,"totalTrials":260,"cells":862},"NPC-15 and\u002For Placebo",{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":876,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":864,"activeCount":8},[],{"trials":866,"activeCount":8},[867],{"nctId":868,"briefTitle":869,"status":54,"phases":870,"primaryCompletion":871,"completion":871,"start":872,"enrollment":77,"conditions":873,"interventions":875},"NCT03475459","Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)",[33],"2018-04-29","2018-04-03",[874],"Qt Interval, Variation in",[861],{"trials":877,"activeCount":8},[],{"trials":879,"activeCount":8},[],{"trials":881,"activeCount":8},[],{"trials":883,"activeCount":8},[],{"intervention":885,"totalTrials":260,"cells":886},"sirolimus",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":901,"PHASE3":903,"PHASE4":905,"NA":907},{"trials":888,"activeCount":8},[],{"trials":890,"activeCount":8},[891],{"nctId":892,"briefTitle":893,"status":54,"phases":894,"primaryCompletion":895,"completion":895,"start":896,"enrollment":897,"conditions":898,"interventions":900},"NCT03765944","Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets",[33],"2018-12-29","2018-12-05",10,[899],"Bioequivalence Study",[885],{"trials":902,"activeCount":8},[],{"trials":904,"activeCount":8},[],{"trials":906,"activeCount":8},[],{"trials":908,"activeCount":8},[],{"intervention":910,"totalTrials":260,"cells":911},"NPC-12G Gel 0.2%",{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":926,"PHASE3":928,"PHASE4":930,"NA":932},{"trials":913,"activeCount":8},[],{"trials":915,"activeCount":8},[916],{"nctId":917,"briefTitle":918,"status":54,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"enrollment":77,"conditions":922,"interventions":924},"NCT03972462","NPC-12G Gel 0.2% Sirolimus PK Bridging Study",[33],"2019-06-17","2019-05-31",[923],"Bioavailability Study",[910,925],"Rapamune® 2 mg",{"trials":927,"activeCount":8},[],{"trials":929,"activeCount":8},[],{"trials":931,"activeCount":8},[],{"trials":933,"activeCount":8},[],{"intervention":925,"totalTrials":260,"cells":935},{"EARLY_PHASE1":936,"PHASE1":938,"PHASE2":944,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":937,"activeCount":8},[],{"trials":939,"activeCount":8},[940],{"nctId":917,"briefTitle":918,"status":54,"phases":941,"primaryCompletion":920,"completion":920,"start":921,"enrollment":77,"conditions":942,"interventions":943},[33],[923],[910,925],{"trials":945,"activeCount":8},[],{"trials":947,"activeCount":8},[],{"trials":949,"activeCount":8},[],{"trials":951,"activeCount":8},[]]